加拿大Med BioGene Inc.  www.medbiogene.com
Med BioGene Inc. (溫哥華，Vancouver)是以發(fā)展基因體科技為主，進(jìn)行癌癥及心血管疾病檢測試劑商業(yè)化的公司
Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests.
Med BioGene’s lead product under development is LungExpress Dx™, a test for early-stage non-small-cell lung cancer that analyzes the molecular profile of a patient’s tumour to provide information to assist in tailoring treatment for that specific patient. LungExpress Dx™ is the first and only gene expression-based test for non-small-cell lung cancer shown to assist in determining a patient's benefit from chemotherapy and prognosis for survival.
Med BioGene expects to commercialize LungExpress Dx™ in the United States in the second half of 2009.

Med BioGene was founded in 2002 and its state-of-the-art laboratory and offices are located in Discovery Park on the University of British Columbia campus. Med BioGene's common shares are listed on the TSX Venture Exchange under the symbol "MBI".